PMC:7048180 / 177-1659
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T3 | 453-460 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T4 | 659-667 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T5 | 1216-1223 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 111-121 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T3 | 350-358 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T4 | 412-416 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T5 | 624-632 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T6 | 1016-1036 | Disease | denotes | 2019-nCoV infections | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 1077-1085 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 1176-1184 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T9 | 1268-1276 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 56-59 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T4 | 105-110 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T5 | 152-153 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 172-177 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T7 | 622-623 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T8 | 642-647 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T9 | 1291-1294 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T10 | 1295-1296 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T2 | 227-236 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T3 | 453-460 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T4 | 717-719 | Chemical | denotes | KD | http://purl.obolibrary.org/obo/CHEBI_73601 |
T5 | 736-743 | Chemical | denotes | epitope | http://purl.obolibrary.org/obo/CHEBI_53000 |
T6 | 1216-1223 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 0-185 | Sentence | denotes | The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. |
T8 | 186-258 | Sentence | denotes | Currently, however, there is no specific antiviral treatment or vaccine. |
T9 | 259-581 | Sentence | denotes | Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. |
T10 | 582-731 | Sentence | denotes | Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). |
T11 | 732-819 | Sentence | denotes | The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. |
T12 | 820-1037 | Sentence | denotes | These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. |
T13 | 1038-1482 | Sentence | denotes | Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD. |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
34 | 780-784 | Gene | denotes | ACE2 | Gene:59272 |
35 | 1155-1159 | Gene | denotes | ACE2 | Gene:59272 |
36 | 21-43 | Species | denotes | 2019 novel coronavirus | Tax:2697049 |
37 | 45-54 | Species | denotes | 2019-nCoV | Tax:2697049 |
38 | 105-110 | Species | denotes | human | Tax:9606 |
39 | 172-177 | Species | denotes | human | Tax:9606 |
40 | 336-345 | Species | denotes | 2019-nCoV | Tax:2697049 |
41 | 350-358 | Species | denotes | SARS-CoV | Tax:694009 |
42 | 437-446 | Species | denotes | 2019-nCoV | Tax:2697049 |
43 | 571-580 | Species | denotes | 2019-nCoV | Tax:2697049 |
44 | 624-632 | Species | denotes | SARS-CoV | Tax:694009 |
45 | 702-711 | Species | denotes | 2019-nCoV | Tax:2697049 |
46 | 805-814 | Species | denotes | 2019-nCoV | Tax:2697049 |
47 | 1077-1085 | Species | denotes | SARS-CoV | Tax:694009 |
48 | 1176-1184 | Species | denotes | SARS-CoV | Tax:694009 |
49 | 1200-1209 | Species | denotes | 2019-nCoV | Tax:2697049 |
50 | 1268-1276 | Species | denotes | SARS-CoV | Tax:694009 |
51 | 1281-1290 | Species | denotes | 2019-nCoV | Tax:2697049 |
52 | 1468-1477 | Species | denotes | 2019-nCoV | Tax:2697049 |
53 | 412-420 | Species | denotes | SARS CoV | Tax:694009 |
54 | 642-647 | Species | denotes | human | Tax:9606 |
55 | 669-675 | Chemical | denotes | CR3022 | |
56 | 747-753 | Chemical | denotes | CR3022 | |
57 | 847-853 | Chemical | denotes | CR3022 | |
58 | 1131-1137 | Chemical | denotes | CR3014 | |
59 | 111-121 | Disease | denotes | infections | MESH:D007239 |
60 | 137-143 | Disease | denotes | deaths | MESH:D003643 |
61 | 1016-1036 | Disease | denotes | 2019-nCoV infections | MESH:C000657245 |